Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.88 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | MGLL | Q99685 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 9/20 | 0.47 |
| ▸ | ERN1 | O75460 | 2/20 | 0.43 |
| ▸ | LPL | P06858 | 1/20 | 0.43 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8675 | 0.94 | ENPP2 (1.00) | ENPP2CA2CA1PTGS2LPL | |
| SCHEMBL10300269 | 0.82 | PTGS2 (0.62) | ENPP2CA2PTGS2KIF11 | |
| SCHEMBL7677302 | 0.82 | PTGS2 (0.62) | ENPP2CA2PTGS2KIF11 | |
| SCHEMBL29129729 | 0.79 | ENPP2 (0.61) | ENPP2PTGS2 | |
| SCHEMBL806835 | 0.76 | CA2 (0.78) | ENPP2CA2CA1MGLLLPL | |
| SCHEMBL13667445 | 0.76 | CA2 (0.78) | ENPP2CA2CA1MGLLLPL | |
| SCHEMBL18394607 | 0.76 | CA2 (0.78) | ENPP2CA2CA1MGLLLPL | |
| SCHEMBL2557507 | 0.76 | ENPP2 (0.52) | ENPP2PTGS2 | |
| SCHEMBL15771185 | 0.76 | ENPP2 (0.56) | ENPP2PTGS2KIF11 | |
| SCHEMBL388018 | 0.76 | ENPP2 (0.86) | ENPP2CA2CA1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9556193-B2 | Benzimidazole hexahydrofuro[3,2-b]furan derivatives | Merck Shapr & Dohme Corp. (US) | 2017-01-31 | — | — | US | disclosed |
| US-20150218183-A1 | NOVEL BENZIMIDAZOLE HEXAHYDROFURO[3,2-B]FURAN DERIVATIVES | MERCK SHARP & DOHME LLC | 2015-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218183-A1 | NOVEL BENZIMIDAZOLE HEXAHYDROFURO[3,2-B]FURAN DERIVATIVES | PRKAG3, PRKAG2, PRKAB2 | ENPP2 2945/4885CA2 3192/4885CA1 4880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.